BioPharmCatalyst

We compared the closing prices of every biotech company who released earnings this week, 11/2-11/6 with their previous close last Friday, 10/30. Here's the top 10 ⬇

$MTVA reported positive interim Phase 1 data for DA-1726, a dual GLP-1/glucagon receptor agonist, demonstrating 68% placebo-adjusted liver fat reduction and 13.5% placebo-adjusted weight loss after 16 weeks. Ten of 12 treated participants achieved at least 30% liver fat reduction, versus none on placebo.
$MTVA $CDT $DWTX $CVRX $TMDX $FTH $FLGT $ANVS $BDSX $BDMD

For more biotech updates, join us on 🔗 BioPharmCatalyst 📰 Articles section

BioPharmCatalyst Weekly #Watchlist

November 6, 2026: BioPharmCatalyst Weekly Watchlist: Key Phase 3 catalysts left for the quarter

$SLS $IVA $KPTI $IMCR $OCS $SLGL $PRTC $ENGN $PTN $CYBN $MLTX

Links in thread below:

$ETON reported preliminary ET-700 pilot study data showing better GI tolerability than GALZIN (8% vs. 67% adverse events, n=12/arm), but weaker copper absorption inhibition (12% vs. 46% reduction in hepatic uptake; placebo +11%). Eton plans to test faster-release formulations in 2027 to improve efficacy. Results from this four-week study in healthy volunteers remain preliminary.

$INO $SPRY $BDMD $BDSX $ETON $INGN $ADVB $GTBP $EVGN robinhood:0x351f65928a40657c31f51bb543f8bb3844d123fa

See More Pre-market Movers at BioPharmCatalyst in the Articles Menu

$LABT redeemed all remaining Series C preferred shares for $1.27M in cash, removing conversion dilution, financing restrictions, and stock overhang. With zero preferred stock or debt, capital structure flexibility improves, though cash for clinical development is modestly reduced.

$LABT $BDMD $AKBA $DTIL $ANVS $XERS $ADMA $KLRS $NIVF $INM

For more biotech updates, join us on 🔗 BioPharmCatalyst 📰 Articles section